Circular-15-of-2022-Safety-measures-for-sodium-valproate-and-the-risk-of-congenital-malformations-in-neonates-and-neurodevelopmental-disorders-in-children-exposed-to-sodium-valproate-during-pregnancy

Circular-15-of-2022-Safety-measures-for-sodium-valproate-and-the-risk-of-congenital-malformations-in-neonates-and-neurodevelopmental-disorders-in-children-exposed-to-sodium-valproate-during-pregnancy52 DownloadsDownload Now!Size: 156MBPublished: July 25, 2022

View More Circular-15-of-2022-Safety-measures-for-sodium-valproate-and-the-risk-of-congenital-malformations-in-neonates-and-neurodevelopmental-disorders-in-children-exposed-to-sodium-valproate-during-pregnancy

Circular 3 of 2022 – Clarification of Conditions for Medicines Registration Requirements and Subsequent Expansion of Registration Certificate, Section 15 Format Annexure

Circular 3 of 2022 – Clarification of Conditions for Medicines Registration Requirements and Subsequent Expansion of Registration Certificate, Section 15…

View More Circular 3 of 2022 – Clarification of Conditions for Medicines Registration Requirements and Subsequent Expansion of Registration Certificate, Section 15 Format Annexure